(NASDAQ: DXCM) Dexcom's forecast annual revenue growth rate of 14.63% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.25%.
Dexcom's revenue in 2026 is $4,515,900,000.On average, 33 Wall Street analysts forecast DXCM's revenue for 2026 to be $2,084,636,973,840, with the lowest DXCM revenue forecast at $1,978,942,564,128, and the highest DXCM revenue forecast at $2,193,841,530,000. On average, 30 Wall Street analysts forecast DXCM's revenue for 2027 to be $2,352,968,168,976, with the lowest DXCM revenue forecast at $2,192,281,464,912, and the highest DXCM revenue forecast at $2,509,364,694,048.
In 2028, DXCM is forecast to generate $2,670,051,398,112 in revenue, with the lowest revenue forecast at $2,300,705,988,528 and the highest revenue forecast at $2,872,469,843,280.